Tilray Brands Reports Narrower Q2 Loss Despite Mixed Sales Performance
Tilray (TLRY) narrows Q2 losses to $43.5M with 3% revenue growth driven by cannabis gains, though beverage sales decline 21% amid international expansion strategy.
/ 3 items
#TLRY↓
Trump Orders Move to Reschedule Cannabis, Easing Medical and Business Rules
President Trump signs an executive order to shift cannabis to Schedule III, potentially expanding medical use, research, and business opportunities nationwide.
Trump Signals Major Shift on U.S. Cannabis Policy as Pot Stocks Surge
Cannabis stocks jumped after reports that President Trump may push to reclassify marijuana to Schedule III, easing restrictions and boosting industry prospects.